New Horizon Health (HKSE:06606) Other Stockholders Equity: HK$-4,494 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06606 New Horizon Health Ltd HKSE:06606
35 GF Score
Price HK$14.14
View Full Analysis

What is New Horizon Health Other Stockholders Equity?

New Horizon Health HKSE:06606 35 Other Stockholders Equity is HK$-4,494 Mil as of Jun. 2023. GuruFocus rates HKSE:06606 with a GF Score™ of 35/100.

New Horizon Health's Other Stockholders Equity for the quarter that ended in Jun. 2023 was HK$-4,494 Mil.

New Horizon Health's quarterly Other Stockholders Equity increased from Jun. 2022 (HK$-5,088 Mil) to Dec. 2022 (HK$-4,800 Mil) and increased from Dec. 2022 (HK$-4,800 Mil) to Jun. 2023 (HK$-4,494 Mil).

New Horizon Health's annual Other Stockholders Equity declined from Dec. 2020 (HK$-1,433 Mil) to Dec. 2021 (HK$-5,249 Mil) but then increased from Dec. 2021 (HK$-5,249 Mil) to Dec. 2022 (HK$-4,800 Mil).

New Horizon Health Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for New Horizon Health's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

New Horizon Health Other Stockholders Equity Chart

New Horizon Health Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Other Stockholders Equity
-359.71 -460.51 -1,432.98 -5,249.10 -4,799.65

New Horizon Health Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only -4,947.70 -5,249.10 -5,088.39 -4,799.65 -4,493.83
HKSE:06606
35GF Score
New Horizon Health Ltd HKSE:06606
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

New Horizon Health Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of HK$-4,494 Mil mean?
New Horizon Health (HKSE:06606) has a Other Stockholders Equity of HK$-4,494 Mil as of Jun. 2023. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on New Horizon Health and its competitors.
Is New Horizon Health's Other Stockholders Equity too high?
New Horizon Health's current Other Stockholders Equity is HK$-4,494 Mil. Overall, New Horizon Health has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does New Horizon Health's Other Stockholders Equity compare to ABT and SYK?
New Horizon Health's Other Stockholders Equity of HK$-4,494 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on New Horizon Health and its competitors. New Horizon Health's current Other Stockholders Equity is HK$-4,494 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Horizon Health stock overvalued right now?
New Horizon Health (HKSE:06606) has a current Other Stockholders Equity of HK$-4,494 Mil. The current Other Stockholders Equity is HK$-4,494 Mil. New Horizon Health's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For New Horizon Health (HKSE:06606), the current Other Stockholders Equity is HK$-4,494 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

New Horizon Health Business Description

Address 400 Jiang’er Road, 13th Floor, T1 Building, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
35GF Score

Get the complete analysis for HKSE:06606

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$14.14
Price